Precursor T-lymphoblastic lymphoma in a patient after successful treatment of acute promyelocytic leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A10224437" target="_blank" >RIV/61989592:15110/09:10224437 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Precursor T-lymphoblastic lymphoma in a patient after successful treatment of acute promyelocytic leukemia

Popis výsledku v původním jazyce

Introduction: Acute promyelocytic leukemia (APL) is a relatively rare subtype of acute myeloid leukemia. It has become the best curable subtype of acute leukemias in adults due to the inclusion of all-trans-retinoic acid (ATRA) in the treatment. Despitethe efficacy of ATRA, chemotherapy must be added in APL patients in order to maintain durable complete remission. However, chemotherapy administration is inevitably related to many complications, including the risk of secondary malignancies. T-lymphoblastic lymphoma (T-LBL) is an infrequent disease that belongs to highly aggressive lymphomas group. Case report: The authors describe a 25-year-old woman treated for APL in 2002 and developed precursor T-LBL five years later. Conclusion: Several cases of secondary acute lymphoblastic leukemias in ?cured? APL patients have been described, but probably no patient with secondary precursor T-LBL. Secondary malignancies has become one of the topics discussed (not only) in APL patients. It is app

Název v anglickém jazyce

Precursor T-lymphoblastic lymphoma in a patient after successful treatment of acute promyelocytic leukemia

Popis výsledku anglicky

Introduction: Acute promyelocytic leukemia (APL) is a relatively rare subtype of acute myeloid leukemia. It has become the best curable subtype of acute leukemias in adults due to the inclusion of all-trans-retinoic acid (ATRA) in the treatment. Despitethe efficacy of ATRA, chemotherapy must be added in APL patients in order to maintain durable complete remission. However, chemotherapy administration is inevitably related to many complications, including the risk of secondary malignancies. T-lymphoblastic lymphoma (T-LBL) is an infrequent disease that belongs to highly aggressive lymphomas group. Case report: The authors describe a 25-year-old woman treated for APL in 2002 and developed precursor T-LBL five years later. Conclusion: Several cases of secondary acute lymphoblastic leukemias in ?cured? APL patients have been described, but probably no patient with secondary precursor T-LBL. Secondary malignancies has become one of the topics discussed (not only) in APL patients. It is app

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Onkologie

ISSN

0378-584X

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

8-9

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

3

Strana od-do

513-515

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—